Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.

Higgins RJ, Dickinson PJ, LeCouteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN.

J Neurooncol. 2010 May;98(1):49-55. doi: 10.1007/s11060-009-0072-5. Epub 2009 Dec 5.

PMID:
19967449
2.

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.

Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, Hesselager G, Ponten F, Smits A, Sooman L, Alafuzoff I.

Histopathology. 2014 Feb;64(3):365-79. doi: 10.1111/his.12252. Epub 2013 Nov 5.

3.

Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas.

Fraser AR, Bacci B, le Chevoir MA, Long SN.

Vet Pathol. 2016 Nov;53(6):1131-1137. Epub 2016 May 6.

PMID:
27154542
4.

Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.

Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blümcke I, von Deimling A, Schlegel U.

J Neurosurg. 1996 Oct;85(4):634-41.

PMID:
8814167
5.

EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.

Burel-Vandenbos F, Benchetrit M, Miquel C, Fontaine D, Auvergne R, Lebrun-Frenay C, Cardot-Leccia N, Michiels JF, Paquis-Flucklinger V, Virolle T.

J Neurooncol. 2011 Apr;102(2):171-8. doi: 10.1007/s11060-010-0308-4. Epub 2010 Jul 24.

PMID:
20652725
6.

Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.

Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN.

Mol Cancer Res. 2006 Dec;4(12):927-34.

7.

[Histological classification of human gliomas: state of art and controversies].

Figarella-Branger D, Bouvier C.

Bull Cancer. 2005 Apr;92(4):301-9. French.

8.
9.

Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.

Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY.

J Neurooncol. 2000 Jun;48(2):103-11.

PMID:
11083073
10.

IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.

Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L, Sawaya R, Bruner JM, Fuller GN, Zhang W.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16675-9. doi: 10.1073/pnas.0900807106. Epub 2009 Sep 16.

11.

Presence of neural progenitors in spontaneous canine gliomas: A histopathological and immunohistochemical study of 20 cases.

Fernández F, Deviers A, Dally C, Mogicato G, Delverdier M, Cauzinille L, Gnirs K, Añor S, de la Fuente C, Fondevila D, Pumarola M.

Vet J. 2016 Mar;209:125-32. doi: 10.1016/j.tvjl.2015.10.039. Epub 2015 Nov 10.

PMID:
26831167
12.

Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.

Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G.

J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31.

PMID:
8965097
13.

Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas.

de la Fuente C, Pumarola M, Blasco E, Fernández F, Viu J, Añor S.

Vet J. 2014 Jun;200(3):387-92. doi: 10.1016/j.tvjl.2014.03.021. Epub 2014 Mar 26.

PMID:
24745770
14.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Review. French.

PMID:
18565348
15.

DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, Nelson HH, Stokoe D, Wiemels JL, Chang SM, Prados MD, Tihan T, Vandenberg SR, Kelsey KT, Berger MS, Wiencke JK.

Neuro Oncol. 2011 Mar;13(3):280-9. doi: 10.1093/neuonc/noq190.

16.

Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas.

Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, Wang H.

J Neurooncol. 2008 May;88(1):11-7. doi: 10.1007/s11060-008-9529-1. Epub 2008 Feb 2.

PMID:
18246408
17.

COX-2 and c-kit expression in canine gliomas.

Jankovsky JM, Newkirk KM, Ilha MR, Newman SJ.

Vet Comp Oncol. 2013 Mar;11(1):63-9. doi: 10.1111/j.1476-5829.2011.00302.x. Epub 2011 Nov 23.

PMID:
22235799
18.

Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.

Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin LM, Ljubimov AV, Black KL.

Cancer Res. 2001 Jul 15;61(14):5601-10.

19.

IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients.

McDonald KL, O'Sullivan MG, Parkinson JF, Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook RJ, Biggs MT, Little NS, Teo C, Stone G, Robinson BG.

J Neuropathol Exp Neurol. 2007 May;66(5):405-17.

PMID:
17483698
20.

Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.

Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C.

Rev Neurol (Paris). 2011 Oct;167(10):683-90. doi: 10.1016/j.neurol.2011.07.006. Epub 2011 Sep 1. Review.

PMID:
21889777

Supplemental Content

Support Center